Search

Your search keyword '"Åsberg, Anders"' showing total 914 results
Start Over Author "Åsberg, Anders"
914 results on '"Åsberg, Anders"'

203. Recovery of kidney function in patients treated with maintenance dialysis—a report from the ERA-EDTA Registry.

Author

Jakulj, Lily, Kramer, Anneke, Åsberg, Anders, Meester, Johan de, Pablos, Carmen Santiuste de, Helve, Jaakko, Hemmelder, Marc H, Hertig, Alexandre, Arici, Mustafa, Bell, Samira, Mercadal, Lucile, Diaz-Corte, Carmen, Palsson, Runolfur, Sanchez, Manuel Benitez, Kerschbaum, Julia, Collart, Frederic, Massy, Ziad A, Jager, Kitty J, and Noordzij, Marlies

Subjects
KIDNEY physiology, HEMOLYTIC-uremic syndrome, CHRONIC kidney failure, HEMODIALYSIS, THROMBOTIC thrombocytopenic purpura, NECROSIS
Abstract

Open in new tab Download slide Open in new tab Download slide Background Literature on recovery of kidney function (RKF) in patients with end-stage kidney disease treated with maintenance dialysis (i.e. >90 days) is limited. We assessed the incidence of RKF and its associated characteristics in a European cohort of dialysis patients. Methods We included adult patients from the European Renal Association–European Dialysis and Transplant Association Registry who started maintenance dialysis in 1997–2016. Sustained RKF was defined as permanent discontinuation of dialysis. Temporary discontinuation of ≥30 days (non-sustained RKF) was also evaluated. Factors associated with RKF adjusted for potential confounders were studied using Cox regression analyses. Results RKF occurred in 7657 (1.8%) of 440 996 patients, of whom 71% experienced sustained RKF. Approximately 90% of all recoveries occurred within the first 2 years after Day 91 of dialysis. Of patients with non-sustained RKF, 39% restarted kidney replacement therapy within 1 year. Sustained RKF was strongly associated with the following underlying kidney diseases (as registered by the treating physician): tubular necrosis (irreversible) or cortical necrosis {adjusted hazard ratio [aHR] 20.4 [95% confidence interval (CI) 17.9–23.1]}, systemic sclerosis [aHR 18.5 (95% CI 13.8–24.7)] and haemolytic uremic syndrome [aHR 17.3 (95% CI 13.9–21.6)]. Weaker associations were found for haemodialysis as a first dialysis modality [aHR 1.5 (95% CI 1.4–1.6)] and dialysis initiation at an older age [aHR 1.8 (95% CI 1.6–2.0)] or in a more recent time period [aHR 2.4 (95% CI 2.1–2.7)]. Conclusions Definitive discontinuation of maintenance dialysis is a rare and not necessarily an early event. Certain clinical characteristics, but mostly the type of underlying kidney disease, are associated with a higher likelihood of RKF. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

214. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary

Author

Kramer, Anneke, primary, Pippias, Maria, additional, Noordzij, Marlies, additional, Stel, Vianda S, additional, Andrusev, Anton M, additional, Aparicio-Madre, Manuel I, additional, Arribas Monzón, Federico E, additional, Åsberg, Anders, additional, Barbullushi, Myftar, additional, Beltrán, Palma, additional, Bonthuis, Marjolein, additional, Caskey, Fergus J, additional, Castro de la Nuez, Pablo, additional, Cernevskis, Harijs, additional, De Meester, Johan, additional, Finne, Patrik, additional, Golan, Eliezer, additional, Heaf, James G, additional, Hemmelder, Marc H, additional, Ioannou, Kyriakos, additional, Kantaria, Nino, additional, Komissarov, Kirill, additional, Korejwo, Grzegorz, additional, Kramar, Reinhard, additional, Lassalle, Mathilde, additional, Lopot, František, additional, Macário, Fernando, additional, Mackinnon, Bruce, additional, Pálsson, Runólfur, additional, Pechter, Ülle, additional, Piñera, Vicente C, additional, Santiuste de Pablos, Carmen, additional, Segarra-Medrano, Alfons, additional, Seyahi, Nurhan, additional, Slon Roblero, Maria F, additional, Stojceva-Taneva, Olivera, additional, Vazelov, Evgueniy, additional, Winzeler, Rebecca, additional, Ziginskiene, Edita, additional, Massy, Ziad, additional, and Jager, Kitty J, additional

Published
2019
Full Text
View/download PDF

219. Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes

Author

Ville, Simon, Lorent, Marine, Kerleau, Clarisse, Asberg, Anders, Legendre, Christophe, Morelon, Emmanuel, Buron, Fanny, Garrigue, Valérie, Le Quintrec, Moglie, Girerd, Sophie, Ladrière, Marc, Albano, Laetitia, Sicard, Antoine, Glotz, Denis, Lefaucheur, Carmen, Branchereau, Julien, Jacobi, David, Giral, Magali, Reisæter, Anna V., Line, Pål-Dag, Åsberg, Anders, Blancho, Gilles, Branchereau, Julien, Cantarovich, Diego, Chapelet, Agnès, Dantal, Jacques, Deltombe, Clément, Figueres, Lucile, Garandeau, Claire, Giral, Magali, Gourraud-Vercel, Caroline, Hourmant, Maryvonne, Karam, Georges, Kerleau, Clarisse, Meurette, Aurélie, Ville, Simon, Kandell, Christine, Moreau, Anne, Renaudin, Karine, Delbos, Florent, Walencik, Alexandre, Devis, Anne, Masset, Christophe, Kervella, Delphine, Amrouche, Lucile, Anglicheau, Dany, Aubert, Olivier, Bererhi, Lynda, Legendre, Christophe, Loupy, Alexandre, Martinez, Frank, Sberro-Soussan, Rébecca, Scemla, Anne, Zuber, Julien, Méjean, Arnaud, Timsit, Marc Olivier, Eschwege, Pascal, Frimat, Luc, Girerd, Sophie, Hubert, Jacques, Ladriere, Marc, Laurain, Emmanuelle, Leblanc, Louis, Lecoanet, Pierre, Lemelle, Jean-Louis, Badet, Lionel, Brunet, Maria, Buron, Fanny, Cahen, Rémi, Daoud, Sameh, Fournie, Coralie, Grégoire, Arnaud, Koenig, Alice, Lévi, Charlène, Morelon, Emmanuel, Pouteil-Noble, Claire, Rimmelé, Thomas, Thaunat, Olivier, Delmas, Sylvie, Le Quintrec, Moglie, Pernin, Vincent, Serre, Jean-Emmanuel, Glotz, Denis, Lefaucheur, Carmen, Albano, Laetitia, and Sicard, Etienne

Published
2021
Full Text
View/download PDF

220. Proteomics‐Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.

Author

Wegler, Christine, Prieto Garcia, Luna, Klinting, Signe, Robertsen, Ida, Wiśniewski, Jacek R., Hjelmesæth, Jøran, Åsberg, Anders, Jansson‐Löfmark, Rasmus, Andersson, Tommy B., and Artursson, Per

Subjects
BODY weight, ROSUVASTATIN, GASTRIC bypass, LIVER biopsy, PREDICTION models
Abstract

Rosuvastatin is a frequently used probe to study transporter‐mediated hepatic uptake. Pharmacokinetic models have therefore been developed to predict transporter impact on rosuvastatin disposition in vivo. However, the interindividual differences in transporter concentrations were not considered in these models, and the predicted transporter impact was compared with historical in vivo data. In this study, we investigated the influence of interindividual transporter concentrations on the hepatic uptake clearance of rosuvastatin in 54 patients covering a wide range of body weight. The 54 patients were given an oral dose of rosuvastatin the day before undergoing gastric bypass or cholecystectomy, and pharmacokinetic (PK) parameters were established from each patient's individual time‐concentration profiles. Liver biopsies were sampled from each patient and their individual hepatic transporter concentrations were quantified. We combined the transporter concentrations with in vitro uptake kinetics determined in HEK293‐transfected cells, and developed a semimechanistic model with a bottom‐up approach to predict the plasma concentration profiles of the single dose of rosuvastatin in each patient. The predicted PK parameters were evaluated against the measured in vivo plasma PKs from the same 54 patients. The developed model predicted the rosuvastatin PKs within two‐fold error for rosuvastatin area under the plasma concentration versus time curve (AUC; 78% of the patients; average fold error (AFE): 0.96), peak plasma concentration (Cmax; 76%; AFE: 1.05), and terminal half‐life (t1/2; 98%; AFE: 0.89), and captured differences in the rosuvastatin PKs in patients with the OATP1B1 521T

Published
2021
Full Text
View/download PDF

221. Renin-Angiotensin System Blockers and the Risk of COVID-19–Related Mortality in Patients with Kidney Failure

Author

Soler, Maria Jose, Noordzij, Marlies, Abramowicz, Daniel, de Arriba, Gabriel, Basile, Carlo, van Buren, Marjolijn, Covic, Adrian, Crespo, Marta, Duivenvoorden, Raphaël, Massy, Ziad A., Ortiz, Alberto, Sanchez, J. Emilio, Petridou, Emily, Stevens, Kate, White, Colin, Vart, Priya, Gansevoort, Ron T., van der Net, Jeroen B., Essig, Marie, du Buf-Vereijken, Peggy W.G., van Ginneken, Betty, Maas, Nanda, Vogt, Liffert, van Jaarsveld, Brigit C., Jager, Kitty J., Bemelman, Frederike J., Klingenberg-Salahova, Farah, Heenan-Vos, Frederiek, Vervloet, Marc G., Nurmohamed, Azam, Verhofstede, Sabine, Maoujoud, Omar, Malfait, Thomas, Fialova, Jana, Melilli, Edoardo, Favà, Alexandre, Cruzado, Josep M., Perez, Nuria Montero, Lips, Joy, Krepel, Harmen, Adilovic, Harun, Hengst, Maaike, Rydzewski, Andrzej, Gellert, Ryszard, Oliveira, João, Alferes, Daniela G., Zakharova, Elena V., Ambuehl, Patrice Max, Winzeler, Rebecca, Lepeytre, Fanny, Rabaté, Clémentine, Rostoker, Guy, Marques, Sofia, Azasevac, Tijana, Katicic, Dajana, Dam, Marc ten, Krüger, Thilo, Brzosko, Szymon, van Zanen, A.L., Logtenberg, Susan J.J., Fricke, Lutz, Slebe, Jeroen J.P., Kemlin, Delphine, van de Wetering, Jacqueline, Reinders, Marlies E.J., Eiselt, Jaromir, Kielberger, Lukas, El-Wakil, Hala S., ElHafeez, Samar Abd, Canal, Cristina, Facundo, Carme, Ramos, Ana M., Debska-Slizien, Alicja, Veldhuizen, Nicoline M.H., Panagoutsos, Stylianos, Matceac, Irina, Nistor, Ionut, Cordos, Monica, Groeneveld, J.H.M, Jousma, Jolanda, Diekmann, Fritz, Pereira, Tiago Assis, Santos, Augusto Cesar S., Arias-Cabrales, Carlos, Llinàs-Mallol, Laura, Buxeda, Anna, Tàrrega, Carla Burballa, Redondo-Pachon, Dolores, Arenas Jimenez, Maria Dolores, Hofstra, Julia M., Franco, Antonio, Arroyo, David, Rodríguez-Ferrero, Maria Luisa, Manzanos, Sagrario Balda, Sosa Barrios, R. Haridian, Lemahieu, Wim, Bartelet, Karlijn, Dirim, Ahmet Burak, Demir, Erol, Sever, Mehmet Sukru, Turkmen, Aydin, Hollander, Daan A.M.J., Büttner, Stefan, de Vries, Aiko P.J., Meziyerh, Soufian, van der Helm, Danny, Mallat, Marko, Bouwsma, Hanneke, Sridharan, Sivakumar, Petruliene, Kristina, Maloney, Sharon-Rose, Verberk, Iris, van der Sande, Frank M., Christiaans, Maarten H.L., Hemmelder, Marc, Di Luca, Marina, Tuğlular, Serhan Z., Beerenhout, Charles, Luik, Peter T., Kerschbaum, Julia, Tiefenthaler, Martin, Watschinger, Bruno, Adema, Aaltje Y., Stepanov, Vadim A., Zulkarnaev, Alexey B., Turkmen, Kultigin, Fliedner, Anselm, Åsberg, Anders, Mjoen, Geir, Miyasato, Hitoshi, de Fijter, Carola W.H., Pini, Stefano, de Biase, Consuelo, Hilbrands, Luuk, Kerckhoffs, Angele, van de Logt, Anne Els, Maas, Rutger, Lebedeva, Olga, Lopez, Veronica, Reichert, Louis J.M., Verhave, Jacobien, Titov, Denis, Parshina, Ekaterina V., Zanoli, Luca, Marcantoni, Carmelita, van Gils-Verrij, Liesbeth E.A., Harty, John C., Meurs, Marleen, Myslak, Marek, Battaglia, Yuri, Lentini, Paolo, den Deurwaarder, Edwin, Stendahl, Maria, Rahimzadeh, Hormat, Schouten, Marcel, Rychlik, Ivan, Cabezas-Reina, Carlos J., Roca, Ana Maria, Nauta, Ferdau, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, Diaz-Mareque, Anabel, Coca, Armando, Meijers, Björn K.I., Naesens, Maarten, Kuypers, Dirk, Desschans, Bruno, Tonnerlier, Annelies, Wissing, Karl M., Dedinska, Ivana, Pessolano, Giuseppina, Gandolfini, Ilaria, Maggiore, Umberto, Malik, Shafi, Papachristou, Evangelos, Franssen, Casper F.M., Berger, Stefan P., Meijer, Esther, Sanders, Jan Stephan F., Ponikvar, Jadranka Buturović, Pernat, Andreja Marn, Kovac, Damjan, Arnol, Miha, Ekart, Robert, Abrahams, Alferso C., Molenaar, Femke M., van Zuilen, Arjan D., Meijvis, Sabine C.A., Dolmans, Helma, Esposito, Pasquale, Krzesinski, Jean-Marie, Barahira, Jean Damacène, Gallieni, Maurizio, Martin-Moreno, Paloma Leticia, Guglielmetti, Gabriele, Guzzo, Gabriella, Luik, Antinus J., van Kuijk, Willi H.M., Stikkelbroeck, Lonneke W.H., Hermans, Marc M.H., Rimsevicius, Laurynas, Righetti, Marco, Islam, Mahmud, and Braak, Nicole Heitink-ter

Published
2021
Full Text
View/download PDF

222. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

Author

Størset, Elisabet, Hole, Kristine, Midtvedt, Karsten, Bergan, Stein, Molden, Espen, and Åsberg, Anders

Subjects
surgical procedures, operative
Abstract

Aims: Tacrolimus is a cornerstone in modern immunosuppressive therapy after kidney transplantation. Tacrolimus dosing is challenged by considerable pharmacokinetic variability, both between patients and over time after transplantation, partly due to variability in cytochrome P450 3A (CYP3A) activity. The aim of this study was to assess the value of the endogenous CYP3A marker 4β‐hydroxycholesterol (4βOHC) for tacrolimus dose individualization early after kidney transplantation. Methods: Data were obtained from 79 adult kidney transplant recipients who contributed a total of 625 4βOHC measurements and 1999 tacrolimus whole blood concentrations during the first 2 months after transplantation. The relationships between 4βOHC levels and individual estimates of tacrolimus apparent plasma clearance (CL/Fplasma) at different time points after transplantation were investigated using scatterplots and population pharmacokinetic modelling. Results: There was no significant correlation between pre‐transplant 4βOHC levels and tacrolimus CL/Fplasma the first week (r = 0.19 [95% CI −0.03‐0.40]) or between 4βOHC and tacrolimus CL/Fplasma 1 week (r = 0.20 [−0.11‐0.47]), 4 weeks (r = 0.21 [−0.07‐0.46]) or 2 months (r = 0.24 [−0.03‐0.48]) after transplantation (P ≥ 0.06). In the population analysis, time‐varying 4βOHC was not a statistically significant covariate on tacrolimus CL/Fplasma, neither in terms of absolute values (P = 0.11) nor in terms of changes from baseline (P = 0.17). 4βOHC values increased between 1 week and 2 months after transplantation (median change +57% [IQR +22–83%], P < 0.001), indicating increasing CYP3A activity. Contradictorily, tacrolimus CL/Fplasma decreased over the same period (median change −13% [IQR −3 to −26%], P < 0.001). Conclusions: 4βOHC does not appear to have a clinical potential to improve individualization of tacrolimus doses early after kidney transplantation. This research has been accepted and published in the British Journal of Clinical Pharmacology. © 2017 Wiley

Published
2017

225. Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry.

Author

Tantiyavarong, Pichaya, Kramer, Anneke, Heaf, James G, Finne, Patrik, Åsberg, Anders, Cases, Aleix, Caskey, Fergus J, Massy, Ziad A, Jager, Kitty J, and Noordzij, Marlies

Subjects
KIDNEY transplantation, HEMODIALYSIS, GLOMERULAR filtration rate, HIGH density lipoproteins, C-reactive protein
Abstract

Background Kidney transplantation should improve abnormalities that are common during dialysis treatment, like anaemia and mineral and bone disorder. However, its impact is incompletely understood. We therefore aimed to assess changes in clinical indicators after the transition from chronic dialysis to kidney transplantation. Methods We used European Renal Association–European Dialysis and Transplant Association Registry data and included adult dialysis patients for whom data on clinical indicators before and after transplantation (2005–15) were available. Linear mixed models were used to quantify the effect of transplantation and of time after transplantation for each indicator. Results In total, 16 312 patients were included. The mean age at transplantation was 50.1 (standard deviation 14.2) years, 62.9% were male and 70.2% were on haemodialysis before transplantation. Total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglycerides increased right after transplantation but decreased thereafter. All other indicators normalized or approached the target range soon after transplantation and these improvements were sustained for the first 4 years of follow-up. In patients with higher estimated glomerular filtration rate (eGFR) levels (30–60 and >60 mL/min/1.73 m2), the improvement of haemoglobin, ferritin, ionized calcium, phosphate, parathyroid hormone, HDL cholesterol, triglycerides, albumin and C-reactive protein levels was more pronounced than in patients with a lower eGFR (<30 mL/min/1.73 m2). Conclusions Except for total cholesterol, LDL cholesterol and triglycerides, all clinical indicators improved after transplantation. These improvements were related to eGFR. Nevertheless, values remained out of range in a considerable proportion of patients and anaemia and hyperparathyroidism were still common problems. Further research is needed to understand the complex relationship between eGFR and the different clinical indicators. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

226. Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study.

Author

Blom, Kjersti Benedicte, Bergo, Kaja Knudsen, Espe, Emil Knut Stenersen, Rosseland, Vigdis, Grøtta, Ole Jørgen, Mjøen, Geir, Åsberg, Anders, Bergan, Stein, Sanner, Helga, Bergersen, Tone Kristin, Bjørnerheim, Reidar, Skauby, Morten, Seljeflot, Ingebjørg, Waldum-Grevbo, Bård, Dahle, Dag Olav, Sjaastad, Ivar, and Birkeland, Jon Arne

Subjects
GLOMERULAR filtration rate, CARDIAC magnetic resonance imaging, HEART beat, KIDNEYS
Abstract

Purpose: Until recently, it has been believed that donating a kidney not represents any risk for development of cardiovascular disease. However, a recent Norwegian epidemiological study suggests that kidney donors have an increased long-term risk of cardiovascular mortality. The pathophysiological mechanisms linking reduced kidney function to cardiovascular disease are not known. Living kidney donors are screened for cardiovascular morbidity before unilateral nephrectomy, and are left with mildly reduced glomerular filtration rate (GFR) after donation. Therefore, they represent an unique model for investigating the pathogenesis linking reduced GFR to cardiovascular disease and cardiovascular remodelling. We present the study design of Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate (CENS), which is an investigator-initiated prospective observational study on living kidney donors. The hypothesis is that living kidney donors develop cardiovascular remodelling due to a reduction of GFR. Materials and methods: 60 living kidney donors and 60 age and sex matched healthy controls will be recruited. The controls will be evaluated to fulfil the Norwegian transplantation protocol for living kidney donors. Investigations will be performed at baseline and after 1, 3, 6 and 10 years in both groups. The investigations include cardiac magnetic resonance imaging, echocardiography, bone density scan, flow mediated dilatation, laser Doppler flowmetry, nailfold capillaroscopy, office blood pressure, 24-h ambulatory blood pressure, heart rate variability and investigation of microbiota and biomarkers for inflammation, cardiovascular risk and the calcium-phosphate metabolism. Conclusions: The present study seeks to provide new insight in the pathophysiological mechanisms linking reduced kidney function to cardiovascular disease. In addition, we aim to enlighten predictors of adverse cardiovascular outcome in living kidney donors. The study is registered at Clinical-Trials.gov (identifier: NCT03729557). [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

228. Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20–50 years: a study by the ERA–EDTA Registry

Author

Pippias, Maria, primary, Jager, Kitty J, additional, Åsberg, Anders, additional, Berger, Stefan P, additional, Finne, Patrik, additional, Heaf, James G, additional, Kerschbaum, Julia, additional, Lempinen, Marko, additional, Magaz, Ángela, additional, Massy, Ziad A, additional, and Stel, Vianda S, additional

Published
2018
Full Text
View/download PDF

234. Determination of Tacrolimus Concentration and Protein Expression of P-glycoprotein in Single Human Renal Core Biopsies

Author

Krogstad, Veronica, primary, Vethe, Nils Tore, additional, Robertsen, Ida, additional, Hasvold, Grete, additional, Ose, Anne-Marthe Due, additional, Hermann, Monica, additional, Andersen, Anders Mikal, additional, Chan, Joe, additional, Skauby, Morten, additional, Svensson, My Hanna Sofia, additional, Åsberg, Anders, additional, and Christensen, Hege, additional

Published
2018
Full Text
View/download PDF

238. First Scandinavian Protocol for Controlled Donation After Circulatory Death Using Normothermic Regional Perfusion

Author

Foss, Stein, primary, Nordheim, Espen, additional, Sørensen, Dag W., additional, Syversen, Torgunn B., additional, Midtvedt, Karsten, additional, Åsberg, Anders, additional, Dahl, Thorleif, additional, Bakkan, Per A., additional, Foss, Aksel E., additional, Geiran, Odd R., additional, Fiane, Arnt E., additional, and Line, Pål-Dag, additional

Published
2018
Full Text
View/download PDF

245. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL)

Author

Hjelmesæth, Jøran, primary, Åsberg, Anders, additional, Andersson, Shalini, additional, Sandbu, Rune, additional, Robertsen, Ida, additional, Johnson, Line Kristin, additional, Angeles, Philip Carlo, additional, Hertel, Jens Kristoffer, additional, Skovlund, Eva, additional, Heijer, Maria, additional, Ek, Anna-Lena, additional, Krogstad, Veronica, additional, Karlsen, Tor-Ivar, additional, Christensen, Hege, additional, Andersson, Tommy B, additional, and Karlsson, Cecilia, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results